Search results

18 results for ibd

Sorted by Relevance . Sort by Date

  1. Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER, IDKmonitor and Promonitor) in people whose Crohn's disease is losing response to a TNF-alpha inhibitor. This could be through a prospective study, for local audit, or for submission to a registry. (The IBD Registry is being adapted to receive data on TNF-alpha inhibitor levels and antibodies against TNF-alpha inhibitors).

    prospective study, for local audit, or for submission to a registry. (The IBD Registry is being adapted to receive data on TNF-alpha...

  2. Biosimilar medicines (KTT15)

    The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .

  3. The New Faecal Calprotectin Care Pathway

    guidance DG11, for the detection of inflammation in the bowel (i.e. IBS vs IBD). Uptake of this guidance has previously been poor and...